Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2023

31-10-2022 | Obesity | Research article

Association of vaspin rs2236242 with type 2 diabetes mellitus and obesity: a meta-analysis of case-control studies

Authors: S. M. Zain, Y. F. Pung, R. Mohamed

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2023

Login to get access

Abstract

Background

Elevated circulating vaspin levels is linked with type 2 diabetes mellitus (T2DM) and obesity. The genetic basis of the association between vaspin rs2236242 and T2DM and obesity is still being investigated. We executed a meta-analysis to evaluate the magnitude of effect caused by vaspin rs2236242 on T2DM and obesity.

Methods

We searched Pubmed, Embase, MEDLINE, Scopus, Web of Science, and Google Scholar for relevant articles published up to 19 February 2022. Data were extracted and summary estimates of the association between vaspin rs2236242 and T2DM and obesity were assessed. Odds ratios (ORs) and confidence intervals (CIs) were used to measure the effect.

Results

This meta-analysis included 2206 cases and 2715 controls in the T2DM cohort, meanwhile 271 cases and 444 controls in the obesity cohort. The pooled estimates revealed no link between vaspin rs2236242 and T2DM, but allele-A was significantly higher in the controls of the obesity cohort, showing that this single nucleotide polymorphism (SNP) has a reduced obesity risk effect. Sensitivity analysis revealed no studies that would modify the estimates or the heterogeneity. Begg and Mazumdar’s and Egger’s tests indicated no substantial publication bias.

Conclusion

Our meta-analysis provides evidence of significant association between vaspin rs2236242 and reduced risk of obesity but not T2DM.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA. 2005;102(30):10610–5.CrossRefPubMedPubMedCentral Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA. 2005;102(30):10610–5.CrossRefPubMedPubMedCentral
2.
go back to reference Klöting N, Kovacs P, Kern M, et al. Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia. 2011;54(7):1819–23.CrossRefPubMed Klöting N, Kovacs P, Kern M, et al. Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia. 2011;54(7):1819–23.CrossRefPubMed
3.
go back to reference Klöting N, Berndt J, Kralisch S, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun. 2006;339(1):430–6.CrossRefPubMed Klöting N, Berndt J, Kralisch S, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun. 2006;339(1):430–6.CrossRefPubMed
4.
go back to reference Dai R, Dong Z, Qian Y, Han Y. Obese type 2 diabetes mellitus patients have higher serum vaspin concentrations. J Diabetes. 2016;8(3):445–7.CrossRefPubMed Dai R, Dong Z, Qian Y, Han Y. Obese type 2 diabetes mellitus patients have higher serum vaspin concentrations. J Diabetes. 2016;8(3):445–7.CrossRefPubMed
5.
go back to reference Yang W, Li Y, Tian T, Wang L. (2017) Serum vaspin concentration in elderly type 2 diabetes mellitus patients with differing body mass index: A cross-sectional study. BioMed Res Int 4875026. Yang W, Li Y, Tian T, Wang L. (2017) Serum vaspin concentration in elderly type 2 diabetes mellitus patients with differing body mass index: A cross-sectional study. BioMed Res Int 4875026.
6.
go back to reference Breitfeld J, Wiele N, Gutsmann B, et al. Circulating adipokine vaspin is associated with serum lipid profiles in humans. Lipids. 2019;54(4):203–10.CrossRefPubMed Breitfeld J, Wiele N, Gutsmann B, et al. Circulating adipokine vaspin is associated with serum lipid profiles in humans. Lipids. 2019;54(4):203–10.CrossRefPubMed
7.
go back to reference Breitfeld J, Tönjes A, Böttcher Y, et al. Genetic variation in the vaspin gene affects circulating serum vaspin concentrations. Int J Obes. 2013;37(6):861–6.CrossRef Breitfeld J, Tönjes A, Böttcher Y, et al. Genetic variation in the vaspin gene affects circulating serum vaspin concentrations. Int J Obes. 2013;37(6):861–6.CrossRef
8.
go back to reference Kempf K, Rose B, Illig T, et al. Vaspin (SERPINA12) genotypes and risk of type 2 diabetes: Results from the MONICA/KORA studies. Exp Clin Endocrinol Diabetes. 2010;118(3):184–9.CrossRefPubMed Kempf K, Rose B, Illig T, et al. Vaspin (SERPINA12) genotypes and risk of type 2 diabetes: Results from the MONICA/KORA studies. Exp Clin Endocrinol Diabetes. 2010;118(3):184–9.CrossRefPubMed
9.
go back to reference Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRefPubMedPubMedCentral Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRefPubMedPubMedCentral
10.
go back to reference Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–35.CrossRefPubMed Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–35.CrossRefPubMed
12.
go back to reference Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.CrossRefPubMed Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.CrossRefPubMed
14.
go back to reference Abdelhamid AM, Zaafan MA. Association of chemerin rs17173608 and vaspin rs2236242 polymorphisms with type two diabetes mellitus and its impact on their corresponding serum levels in Egyptian population. Biomed J Sci & Tech Res. 2019;15(3):11340–5. Abdelhamid AM, Zaafan MA. Association of chemerin rs17173608 and vaspin rs2236242 polymorphisms with type two diabetes mellitus and its impact on their corresponding serum levels in Egyptian population. Biomed J Sci & Tech Res. 2019;15(3):11340–5.
15.
go back to reference Abdel-Ghany SM, Sayed AA, El-Deek SEM, et al. Obesity risk prediction among women of Upper Egypt: The impact of serum vaspin and vaspin rs2236242 gene polymorphism. Gene. 2017;626:140–8.CrossRefPubMed Abdel-Ghany SM, Sayed AA, El-Deek SEM, et al. Obesity risk prediction among women of Upper Egypt: The impact of serum vaspin and vaspin rs2236242 gene polymorphism. Gene. 2017;626:140–8.CrossRefPubMed
16.
go back to reference Hosseini M, Nezhadali M, Hedayati M. Association of vaspin rs2236242 gene polymorphism with serum vaspin level, insulin resistance and diabetes in an Iranian diabetic/pre-diabetic population. J Med Biochem. 2021;40(1):33–40.CrossRefPubMedPubMedCentral Hosseini M, Nezhadali M, Hedayati M. Association of vaspin rs2236242 gene polymorphism with serum vaspin level, insulin resistance and diabetes in an Iranian diabetic/pre-diabetic population. J Med Biochem. 2021;40(1):33–40.CrossRefPubMedPubMedCentral
17.
go back to reference Li J, Li Q, Zhu YC, et al (2019) Association of vaspin rs2236242 gene variants with type 2 diabetes and obesity in a Chinese population: A prospective, single-center study. J Cell Physiol:Epub ahead of print. Li J, Li Q, Zhu YC, et al (2019) Association of vaspin rs2236242 gene variants with type 2 diabetes and obesity in a Chinese population: A prospective, single-center study. J Cell Physiol:Epub ahead of print.
18.
go back to reference Neama ED, Joda TM, Al Jeboori NA. Assessment of vaspin rs2236242 SNP and correlation with metabolic profile in Iraqi patients with T2DM. ” Turk J Physiother Rehabil. 2021;32(3):5166–70. Neama ED, Joda TM, Al Jeboori NA. Assessment of vaspin rs2236242 SNP and correlation with metabolic profile in Iraqi patients with T2DM. ” Turk J Physiother Rehabil. 2021;32(3):5166–70.
19.
go back to reference Rathwa N, Parmar N, Palit SP, Patel R, Ramachandran AV, Begum R. Intron specific polymorphic site of vaspin gene along with vaspin circulatory levels can influence pathophysiology of type 2 diabetes. Life Sci. 2020;243:117285. Epub ahead of print.CrossRefPubMed Rathwa N, Parmar N, Palit SP, Patel R, Ramachandran AV, Begum R. Intron specific polymorphic site of vaspin gene along with vaspin circulatory levels can influence pathophysiology of type 2 diabetes. Life Sci. 2020;243:117285. Epub ahead of print.CrossRefPubMed
20.
go back to reference Zarei A, Kohan L, Fallahi S. Association of vaspin rs2236242 gene polymorphism with overweight and obesity in Iranian women. Iran J Endocrinol Metab. 2014;16(1):20–5. Zarei A, Kohan L, Fallahi S. Association of vaspin rs2236242 gene polymorphism with overweight and obesity in Iranian women. Iran J Endocrinol Metab. 2014;16(1):20–5.
21.
go back to reference von Hippel PT. The heterogeneity statistic I(2) can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15(35):1–8. von Hippel PT. The heterogeneity statistic I(2) can be biased in small meta-analyses. BMC Med Res Methodol. 2015;15(35):1–8.
22.
go back to reference Suliga E, Kozieł D, Cieśla E, et al. Associations between vaspin rs2236242 gene polymorphism, walking time and the risk of metabolic syndrome. Balkan J Med Genet. 2019;22(1):41–8.CrossRefPubMedPubMedCentral Suliga E, Kozieł D, Cieśla E, et al. Associations between vaspin rs2236242 gene polymorphism, walking time and the risk of metabolic syndrome. Balkan J Med Genet. 2019;22(1):41–8.CrossRefPubMedPubMedCentral
23.
go back to reference Al-Homedi Z, Afify N, Memon M, et al. Genetic studies of metabolic syndrome in Arab populations: A Systematic Review and Meta-Analysis. Front Genet. 2021;12(733746):1–8. Al-Homedi Z, Afify N, Memon M, et al. Genetic studies of metabolic syndrome in Arab populations: A Systematic Review and Meta-Analysis. Front Genet. 2021;12(733746):1–8.
24.
go back to reference Blüher M. Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine. 2012;41(2):176–82.CrossRefPubMed Blüher M. Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine. 2012;41(2):176–82.CrossRefPubMed
25.
go back to reference Youn BS, Klöting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008;57(2):372–7.CrossRefPubMed Youn BS, Klöting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes. 2008;57(2):372–7.CrossRefPubMed
Metadata
Title
Association of vaspin rs2236242 with type 2 diabetes mellitus and obesity: a meta-analysis of case-control studies
Authors
S. M. Zain
Y. F. Pung
R. Mohamed
Publication date
31-10-2022
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2023
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-022-01119-8

Other articles of this Issue 1/2023

Journal of Diabetes & Metabolic Disorders 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine